Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 9,705 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $134,965.89.
- On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $135,155.82.
- On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.36, for a total value of $425,476.76.
- On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total value of $445,680.62.
- On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total value of $436,809.10.
Maze Therapeutics Price Performance
Shares of NASDAQ MAZE opened at $26.37 on Wednesday. Maze Therapeutics, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $53.65. The company has a market cap of $1.46 billion, a PE ratio of -10.46 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The business has a 50-day simple moving average of $28.57 and a two-hundred day simple moving average of $30.78.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on MAZE. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. BTIG Research restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average target price of $66.00.
Check Out Our Latest Report on MAZE
Hedge Funds Weigh In On Maze Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after buying an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics in the fourth quarter valued at approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. boosted its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
